Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
(1)
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively
Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x10
9 cells per infusion
Emergence of new T cell clones in the peripheral blood T cell repertoire four months after therapy was observed in patients analyzed from the highest dose level who experienced either a confirmed partial response or stable disease suggesting that modulation of the endogenous immune response may be an important mechanism of action of CYAD-101 in mCRC patients
Celyad Oncology SA: Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
Regulatory News:
Celyad Oncology SA (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors. I am very pleased to welcome Marina to our Board of Directors, stated Filippo Petti, CEO of Celyad Oncology. As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from Marina s wealth of experience as we continue to advance key elements of our pipeline with the goal of developing innovative cell therapies against cancer.
(2)
Regulatory News:
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD) (the Company ), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it has entered into a committed equity purchase agreement ( Purchase Agreement ) for up to $40 million with Lincoln Park Capital Fund, LLC ( LPC ), a Chicago-based institutional investor.
Over the 24-month term of the Purchase Agreement, the Company will have the right to direct LPC to purchase up to an aggregate amount of $40 million American Depositary Shares ( ADSs ), each of which represents one ordinary share of the Company. LPC s maximum obligation under any single regular purchase will not exceed $2.5 million, unless both parties mutually agree to increase the maximum amount of such purchase. The purchase price for the ADSs to be purchased by LPC under a regular purchase will be the equal to
Gilead Sciences, Inc.: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (Filgotinib) Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This announcement follows a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the C